Ocular Betaxolol

  title={Ocular Betaxolol},
  author={Micaela M.-T. Buckley and Karen L. Goa and Stephen P. Clissold},
SummarySynopsisBetaxolol is a lipophilic β-adrenoceptor antagonist relatively selective for β1-adrenoceptors with only weak β2-blocking activity. Used topically in glaucoma and ocular hypertension, betaxolol 0.5% solution produces a reduction in intraocular pressure of between 13 and 30%, an effect comparable with that of ocular timolol. It may usefully be combined with other types of anti-glaucoma agents. The most notable feature of its adverse effect profile is transient local stinging or… 
Betaxolol: A comprehensive profile.
Systemic side effects of glaucoma medications
This review will discuss the systemic adverse effects of carbonic anhydrase inhibitors, sympathomimetics, para-sympathomIMetics, beta blockers, prostaglandin analogs, hyperosmotic agents, and novel glaucoma medications with a stress on pregnant patients, breastfeeding mothers, and paediatric patients.
Wettability and contact angle affect precorneal retention and pharmacodynamic behavior of microspheres
The dual-functioning microspheres presented in this study provide the possibility for improved compliance due to low cytotoxicity and hemolysis, which suggests promising clinical implications.
′Ab Ovo′ Chiral Phases and Chiral Reagents for Liquid Chromatographic Separation and Isolation of Enantiomers
The de‐novo approach of mixing chirally pure reagents or Cu(II)‐L‐amino acid complexes in the slurry of silica gel for preparing TLC plates was reported from author's laboratory and was successful
Comprehensive Pharmacology: Glaucoma
Drugs Acting Through Autonomic System for Ocular Use
This chapter is an attempt to review the autonomic nervous system innervations to the ocular structures, their role in carrying out physiological functions of eye and drugs acting through this system as diagnostic, palliative and curative strategies in various ophthalmic conditions.


Comparison of ophthalmic beta-blocking agents.
  • T. Lesar
  • Medicine, Biology
    Clinical pharmacy
  • 1987
Betaxolol and levobunolol appear to be similar to timolol in controlling IOP in patients with POAG and OHT; additional experience with these agents is needed to assess the advantages and disadvantages of each agent.
Betaxolol: A New β-Adrenergic Blocking Agent for Treatment of Glaucoma
The data suggest that an ophthalmic formulation of betaxolol may have substantial clinical potential for the treatment of glaucoma and blood pressure and pulse rate remained stable throughout the year.
Betaxolol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension.
Betaxolol is an effective alternative to other beta-blocking drugs in patients with essential hypertension, with properties that may offer advantages in some patients, and has been well tolerated in most patients.
Congestive Heart Failure From Betaxolol
An 80-year-old man with long-standing chronic open angle glaucoma was seen, with the following ocular findings: intraocular tensions of persistently 20 to 25 mm Hg, cup-to-disc ratios of 0.85 in each eye, and visual fields that showed dense superior arcuate defects in eachEye.
Betaxolol eye drops as a safe medication to lower intraocular pressure.
It is confirmed the previously reported efficacy and safety of betaxolol in patients with glaucoma and airways disease with satisfactory patient acceptance.
Betaxolol is a relatively selective beta-1 blocker which in most patients is almost as effective as timolol in lowering intraocular pressure, and may be partly additive with dipivefrin.
Additive effect of betaxolol and epinephrine in primary open angle glaucoma.
The results suggest that epinephrine's agonist effect on the outflow channels is mediated through beta 2-adrenergic receptors and that combined therapy with betaxolol andEpinephrine may be clinically useful.
The effect of topical ophthalmic instillation of timolol and betaxolol on lung function in asthmatic subjects.
The severity of timolol-sensitivity correlated with the extent of reduction in baseline percent predicted FEV1 and FVC and with exercise-induced bronchospasm, and the administration of Timolol reduced the bronchodilator response to below the pretimolol value.
Effects of topical betaxolol in ocular hypertensive patients.
Topical 0.25% betaxolol was found to significantly lower intraocular pressure compared with placebo and may be useful in patients with asthma, chronic bronchitis, and certain cardiovascular diseases where timolol maleate therapy may be contraindicated.
Alopecia Possibly Secondary to Topical Ophthalmic β-Blockers
This is the first report of alopecia due to use of topical ophthalmic β-blockers, and the National Registry of Drug-Induced Ocular Side Effects has received reports of 56 cases of alobecia in patients who use oral β- blockers.